Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
The opening of our 1000th pharmacy in Karnataka marks an important step
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The portfolio includes foundational patents on the production, composition, and commercial use of NR
Subscribe To Our Newsletter & Stay Updated
